Looking for a chapter closer to you? Click here.

Research & Technology

Stem Cells . . . Re-educative?

by Kimberly Ford Chisholm 02.17.2012 Lessons Earned

Can stem cells teach a renegade immune system a really important lesson?

Read the full article →

Study Helps Explain Activity of Anti-CD3 in Treating or Preventing Type 1 Diabetes

by JDRF Bay Area 02.10.2012 Research & Technology

JDRF-funded researchers are studying whether an existing drug might preemptively prevent or delay the development of T1D in at-risk individuals.

Read the full article →

More GOOD News from the FDA

by Kimberly Ford Chisholm 02.03.2012 Lessons Earned

Stanford University and the FDA announced a collaboration on January 12, 2012 that will lead to more efficient and effective methods of establishing the safety and efficacy of medications and devices.

Read the full article →

CD8 and nPod: Why People in the T1D Community Should Know What These Mean

by Kimberly Ford Chisholm 01.27.2012 Lessons Earned

What they have observed is at the root of T1D. If we can actually witness the attack of a certain type of cell by another type of cell, at a certain location in the pancreas, we can effectively begin to halt that attack.

Read the full article →

JDRF-Funded Project Identifies Cell that Triggers T1D

by JDRF Bay Area 01.26.2012 Research & Technology

The finding is an important advance that verifies in humans several important disease characteristics shown in mouse studies and provides a key focal point for interrupting the disease process.

Read the full article →

An Enormous Honor

by Kimberly Ford Chisholm 01.13.2012 Lessons Earned

No one living with T1D likes to hear about complications. Unless the news is GOOD.

Read the full article →

Diabetes and Biotechnology: A Shared History…A Hopeful Future

by JDRF Bay Area 12.21.2011 Research & Technology

Dr. Dick Insel, JDRF’s Chief Scientific Officer, and Kerry Morgan, 2011 JDRF Children’s Congress delegate, talk about the future of diabetes and biotechnology.

Read the full article →